Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been reapproved for heart failure (HF) therapy in patients with and without diabetes. However, the initial glucose-lowering indication of SGLT2i has impeded their uses in cardiovascular clinical practice. A challenge of SGLT2i then becomes how t...
Bewaard in:
Hoofdauteurs: | , , , , , , , , , , , , , , |
---|---|
Formaat: | Boek |
Gepubliceerd in: |
Elsevier,
2023-04-01T00:00:00Z.
|
Onderwerpen: | |
Online toegang: | Connect to this object online. |
Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|
Internet
Connect to this object online.3rd Floor Main Library
Plaatsingsnummer: |
A1234.567 |
---|---|
Kopie 1 | Beschikbaar |